Epigenetic Drivers in Pediatric Medulloblastoma

Martine F. Roussel1 · Jennifer L. Stripay1

Published online: 25 November 2017 © The Author(s) 2017. This article is an open access publication

Abstract Epigenetics is the process by which gene expression is regulated by events other than alterations of the genome. This includes DNA methylation, histone modifications, chromatin remodeling, microRNAs, and long non-coding RNAs. Methylation of DNA, chromatin remodeling, and histone modifications regulate the chromatin and access of transcription factors to DNA and in turn gene transcription. Alteration of chromatin is now recognized to be deregulated in many cancers. Medulloblastoma is an embryonal tumor of the cerebellum and the most common malignant brain tumor in children, that occurs only rarely in adults. Medulloblastoma is characterized by four major molecularly and histopathologically distinct groups, wingless (WNT), sonic hedgehog (SHH), group 3 (G3), and group 4 (G4), that, except for WNT, are each now subdivided in several subgroups. Gene expression array, next-generation sequencing, and methylation profiling of several hundred primary tumors by several consortia and independent groups revealed that medulloblastomas harbor a paucity of mutations most of which occur in epigenetic regulators, genetic alterations in oncogenes and tumor suppressors, in addition to copy number alterations and chromosome gains and losses. Remarkably, some tumors have no reported mutations, suggesting that some genes required for oncogenesis might be regulated by epigenetic mechanisms which are still to be uncovered and validated. This review will highlight several epigenetic regulators focusing mainly on histone modifiers identified in medulloblastoma.

Keywords Medulloblastoma · Epigenetics · MYC · MYCN · PRC2

Abbreviations
BET Bromodomain and extraterminal domain
BRD Bromodomain
CDK Cyclin-dependent kinase
ChIP Chromatin immunoprecipitation
CpG C—phosphate—G
CRISPR Clustered regularly interspaced short palindromic repeats
EZH2 Enhancer of zeste 2 polycomb repressive complex 2 subunit
G3 Group 3 medulloblastoma
G4 Group 4 medulloblastoma
H3Kx Histone 3 lysine x
HAT Histone acetyltransferase
HDAC Histone deacetylase
KDM Lysine demethylase
KMT Lysine methyltransferase
LncRNA Long non-coding RNA
MB Medulloblastoma
miRNA MicroRNA
ncRNA Non-coding RNA
PRC Polycomb repressive complex
RISC RNA-induced silencing complex
SHH Sonic hedgehog
shRNA Short hairpin RNA
TALEN Transcription activator-like effector nuclease
TSA Trichostatin A
Introduction

Brain tumors account for the majority of solid malignancies in children, with medulloblastoma (MB) being the most malignant. MB is a heterogeneous class of embryonal cerebellar tumors that experience aberrations in pathways known to play critical roles in cerebellum development [1]. Early gene expression profiling classified MBs in four distinct molecular subtypes: two with mutations in developmental pathways, sonic hedgehog (SHH) and wingless (WNT), and two others, group 3 (G3) characterized by MYC overexpression from amplification in 17% of cases and group 4 (G4) that occurs in the highest number of patients (Fig. 1). Recent analysis of a large cohort of patients using next-generation sequencing, DNA methylation arrays, and RNA-sequencing, now subdivides each of the three subtypes SHH, G3, and G4 into additional subgroups [3–5]. Each major subtype of MB responds differently to the current therapeutic regimen that comprises tumor resection, craniospinal radiation in patients older than 3 years, and combination chemotherapy with a subset of antineoplastic agents including vincristine (antimicrotubular), cisplatin (alkylating), cyclophosphamide (alkylating), carboplatin (platinum-based), and/or lomustine (alkylating) [6, 7]. The addition of targeted therapies is currently being evaluated in clinical trials (Table 1). Current protocols have led in the past decade to increased survival rates up to ~70%, although patients often suffer from severe sequela that greatly impair their quality of adult life [8]. Whereas patients with WNT MB do well with the current therapy, the prognosis for children with G3 MBs harboring MYC amplification or SHH MBs with TP53 mutations and MYCN amplification remains poor [3]. As observed in several pediatric cancers, the mutational landscape of MBs is relatively sparse, with few recurrent genetic alterations in oncogenes and tumor suppressors, microRNAs, long non-coding RNAs (LncRNA), and regulators of DNA methylation, chromatin remodeling, and histone modifications [9]. The relative paucity of recurrent mutations across the spectrum of G3 and G4 tumors suggests that additional, non-mutated, epigenetic regulators might be implicated in shaping the chromatin signature. Besides direct alteration of genes and epigenetic regulators, gene and protein expression can be regulated by microRNAs and LncRNAs that can act as tumor suppressors or oncogenes, depending on tumor type. As a result, all these mechanisms are actively being interrogated for their role in tumorigenesis. Because epigenetic regulation is reversible, it is explored for possible therapeutic targeting. Many companies have developed compounds that target these epigenetic regulators, several of which are in clinical trials and will be highlighted throughout this discussion. This review is not meant to be inclusive of every known epigenetic regulators and their function, but rather to highlight the role of some of them in the pathogenesis of medulloblastoma.

Epigenetic Overview

The heritable changes that do not involve perturbations in nucleotide sequences are referred to collectively as epigenetics. Epigenetic regulation is mediated by DNA methylation,
histone modifications, chromatin remodeling, microRNAs (miRNA), and LncRNAs [10]. One of the most well-characterized epigenetic phenomena is methylation of DNA, which typically ensues at CpG islands in the promoter region of genes resulting in transcriptional repression. Histone modifications including acetylation, methylation, ubiquitylation, phosphorylation, and sumoylation are written, read, and erased by epigenetic modulators. Non-coding RNA (ncRNA) including miRNAs and LncRNAs regulates gene expression (typically gene silencing) at the transcriptional or post-transcriptional level. Epigenetic changes occur spatially and temporally throughout development and influence processes like cell cycle, DNA repair, and cellular differentiation [11]. Epigenetic regulation plays a significant role in cancer, often resulting in the silencing of tumor suppressor genes or activation of oncogenes (Fig. 2). In the case of mutationally “quiet” cancers, there is emerging focus on the role of epigenetics in disease pathogenesis.

### Epigenetic Mutational Landscape in Medulloblastoma

Initial studies by the Washington University/St. Jude Pediatric Cancer Genome Project (PCGP) using next-generation sequencing showed that besides amplification of MYC, MYCN, CCND2/CYCLIN D2, CDK6, and GLI2 and mutations in β-CATENIN, PTCH1, SUFU, and TP53, mutations in epigenetic regulators account for the majority of genetic perturbations in G3 and G4 MBs (Table 2) [9, 12, 13]. The associated spectrum of altered demethylases, acetyltransferases, and nucleosome remodelers further stratifies MB subgroups [9]. The aberrant pattern of H3K4 and H3K27 histone lysine methylation occurs across subgroups in medulloblastoma [14]. Epigenetic alterations can also result in differential messenger RNA (mRNA)/miRNA expression and alternate promoter usage. Notably, many of the somatic mutations in epigenetic regulators identified in MB do not co-occur within individual tumors. As such, bourgeoning technologies like single-cell sequencing in collaboration with validation in mouse models should provide insights into which epigenetic perturbations contribute as drivers or cooperative passengers in MB.

| MB subgroup | Targeted therapy                                      | ClinicalTrials.gov ID |
|-------------|-------------------------------------------------------|-----------------------|
| WNT         | Reduced radiation and chemotherapy dosing            | NCT02724579           |
| SHH         | SHH pathway inhibitors                               | NCT01878617           |
| Non-SHH/WNT | Pemetrexed (folate pathway inhibitor) / gemcitabine (DNA/RNA synthesis inhibitor) | NCT01878617 |

Table 1  Medulloblastoma subgroups and specific experimental therapeutics. Ongoing clinical trials using targeted therapies or repurposed drugs dictated by MB subgroup biology, genetic signature, or molecular profile

**Fig. 2** Epigenetic regulation of gene transcription by histone modifications. Histone modifications drive changes in gene expression depending on the type, extent, and location of acetylation or methylation marks. Histone acetylation (Ac) at promoters and methylation (Me) of H3K4 throughout a gene leads to activation of gene expression, while methylation of H3K27 or H3K9, particularly in promoter regions, represses transcription. Each nucleosome is composed of two copies of each histone H2A, H2B, H3, and H4.
DNA Methylation

Genome-wide DNA methylation arrays currently examine 850,000 CpG sites across CpG islands and untranslated regions (UTRs). Not only have these arrays helped confirm the four major subgroups of MBs, but they identified multiple subtypes within them [15]. These analyses suggest that DNA methylation plays a major role in the pathogenesis of MB by repressing genes to avoid cell differentiation and cell death [14]. Initial studies using bisulfite conversion of genomic DNA followed by amplification by polymerase chain reaction (PCR) revealed several tumor suppressor genes silenced by hypermethylation of CpG-dense promoters including CDKN2A, HIC1, and RASSF1 [16, 17]. Other approaches identified repressed genes, including PTCH1, the negative regulator of SHH signaling, the SFRP family, inhibitors of the WNT signaling pathway, and the transcriptional repressor ZIC2, among others [18]. Some of the first epigenetic drugs proposed as anti-cancer therapeutics were DNA methylation inhibitors including 5-azacytidine (5-aza-CR) and 5-aza-2'-deoxycytidine (5-aza-CdR). These cytotoxic agents incorporate into DNA and trap DNA methyltransferases, preventing activity and restoring expression of tumor suppressor genes [10].

Histone Modifiers

Histones are regulated by modification of their amino-terminal tail including methylation, acetylation, phosphorylation, and ubiquitination, each of which is driven by specific enzymes within protein complexes (Fig. 3) [10]. Extensive molecular analysis of MBs identified somatic copy number aberrations and mutations in histone lysine methyltransferases (HMTs, called “writers”), demethylases (“erasers”), acetyltransferases (HAT), deacetylases (HDACs), and members of the polycomb transcriptional repressor complex, PRC2 and PRC1 (Fig. 4) [19]. Interestingly, individual histone modifiers are rarely found mutated in more than one tumor, and their frequency is relatively low from 1 to 5.8% across the four MB subgroups [9]. Inactivating mutations in MLL2/KMT2D and MLL3/KMT2C, two lysine methyltransferases that promote H3K4me2/3 associated with active chromatin and gene expression, occur in 16% of MB, with recurrence noted in SHH and G4, pointing to their role as tumor suppressors in medulloblastoma.

Histone acetyltransferases (HATs) act to relax histone-DNA interactions and promote gene transcription. Though less studied in the context of MB, HATs play a crucial role in brain development, and downregulation of the H4K16 HAT, hMOF, has been associated with poorer outcomes in MB patients [20]. Somatic alterations that target HATs are overrepresented in SHH subgroup tumors [4]. In contrast, histone deacetylases (HDACs) promote chromatin condensation and abrogate gene transcription related to cell cycle regulation and cell differentiation. Upregulation of several HDACs (HDAC5 and HDAC9, SIRT1, etc.) identified in MB contributes to aberrant cell cycle progression [21, 22]. With the goal of re-establishing normal histone acetylation patterns, HDAC inhibitors are being explored as possible therapeutics. Valproic acid, an HDAC inhibitor, induces senescence in MB cells and inhibits tumor growth by inducing expression of the cyclin-dependent kinase (CDK) inhibitory protein p21Cip1 [23]. Another HDAC inhibitor, trichostatin A (TSA), increases expression of the negative regulators of the WNT pathway, main drivers in this MB subgroup.

Alterations in histone demethylases are found in G3 and G4 medulloblastoma, consistent with aberrant histone methylation at H3K27 and H3K4. Transcriptional effectors of lysine demethylase (KDM) regulation include genes involved in cell cycle control, differentiation, and

| Gene          | WNT | SHH | G3 | G4 | Ref. |
|---------------|-----|-----|----|----|------|
| ARD1A         | ✓   | ✓   | ✓  | ✓  | [4]  |
| ARID2         | ✓   | ✓   | ✓  | ✓  | [4]  |
| BCOR          | ✓   | ✓   | ✓  | ✓  | [4, 12] |
| CDH1          | ✓   |     |    |    | [9]  |
| CHD7          | ✓   | ✓   | ✓  |    | [9]  |
| CREBBP        | ✓   | ✓   | ✓  | ✓  | [4, 9] |
| GPS3          | ✓   | ✓   | ✓  |    | [12] |
| GSE1          | ✓   | ✓   | ✓  |    | [4]  |
| KDM1A         | ✓   |     |    |    | [9]  |
| KDM3A         | ✓   |     |    |    | [9]  |
| KDM4C         | ✓   | ✓   | ✓  |    | [9]  |
| KDM5A         | ✓   | ✓   | ✓  |    | [9]  |
| KDM5B         | ✓   |     |    |    | [9]  |
| KDM6A/UTX     | ✓   | ✓   | ✓  |    | [4, 9, 12, 13] |
| KDM7A         | ✓   |     |    |    | [9]  |
| LDB1          | ✓   |     |    |    | [12] |
| MLL2/KMT2D    | ✓   | ✓   | ✓  |    | [4, 9, 12, 13] |
| MLL3/KMT2C    | ✓   | ✓   | ✓  |    | [4, 12] |
| NCO2          | ✓   | ✓   | ✓  |    | [12] |
| PRDM6<sup>a</sup> | ✓   |     |    |    | [4]  |
| SMARCA4       | ✓   | ✓   | ✓  |    | [4, 9, 12, 13] |
| ZMETM3        | ✓   | ✓   | ✓  |    | [4, 9] |

<sup>a</sup>Enhancer hijacking drives overexpression of PRDM6

Table 2 Mutations in epigenetic regulators in medulloblastoma. Check marks indicate mutations of an indicated epigenetic regulator gene in at least one tumor sample pooled from four whole genome sequencing (WGS) studies.
pluripotency. Mutations in six KDM family members have been identified, with inactivating mutations in $KDM6A/\text{UTX}$ being one of the most common recurrent events in G4 MB [9, 19].

Another class of epigenetic regulators, bromodomain (BRD) and extraterminal (BET)-containing proteins, recognizes and binds acetylated histone sidechains on open chromatin and recruits the transcriptional machinery. BET/BRD proteins control MYC levels [24, 25], one of the most common drivers in G3 MB [9]. A small molecule BET inhibitor (JQ1) exhibits potent antitumor activity in preclinical studies of medulloblastoma, and is currently being evaluated for chemical modification and therapeutic potential [26, 27].
The polycomb repressor complex PRC2 plays an important role on differentiation, maintenance of cell identity, and proliferation [28, 29]. It is miss-regulated in many cancers in which it can have oncogenic or tumour-suppressive activity depending on context. PRC2 is composed of EZH2, EED, SUZ12, JARID2, and RBAp46.48. EZH2, the catalytic partner of the polycomb repressor PRC2, is responsible for transferring methyl groups onto lysine 27 of histone 3 (H3K27me3) to contribute to chromatin compaction and transcriptional repression [30]. EZH2 is critical for normal development since its deletion in mice is embryonic lethal [31]. EZH2 is overexpressed in many cancers in which it either plays a role as an oncogene, as seen in most cases studied, or as a tumor suppressor [32, 33]. Studies by many consortia and other groups found that a subset of G3 and G4 MBs, but not SHH and WNT tumors, are characterized by high levels of EZH2 expression and H3K27me3 marks but impaired H3K4 methylation, a combination of histone marks consistent with a stem/progenitor cell-like identity that typifies G3 MBs (Fig. 5) [14]. G3 MBs can also be distinguished by their pattern of active enhancers marked by H3K27acetylation (ac) and H3K4me1 based on chromatin immunoprecipitation followed by sequencing (ChIP-seq) analysis [9, 19].

Remarkably, KDM6A/UTX mutations occurring throughout the entire gene leading to complete protein loss are mutually exclusive with EZH2 overexpression, suggesting a critical role for H3K27me3 in MB tumorigenesis and potential clinical vulnerability (Fig. 6) [14]. These results suggested that EZH2 might be an oncogene, whereas KDM6A/UTX might have tumor-suppressive activity. To address whether EZH2 might have oncogenic activity, we recently deleted EZH2 and SUZ12 in mouse and human G3 MBs by TALEN and CRISPR-Cas9 gene editing approaches [33]. Contrary to our expectation, loss of the PRC2 complex accelerated tumor progression suggesting that the polycomb repressor PRC2 has tumor-suppressive activity. We showed that the catalytic activity of EZH2 is required for acceleration of tumor progression. We showed that the catalytic activity of EZH2 is required for acceleration of tumor progression and potential clinical vulnerability (Fig. 6) [14]. These results suggested that EZH2 might be an oncogene, whereas KDM6A/UTX might have tumor-suppressive activity. To address whether EZH2 might have oncogenic activity, we recently deleted EZH2 and SUZ12 in mouse and human G3 MBs by TALEN and CRISPR-Cas9 gene editing approaches [33]. Contrary to our expectation, loss of the PRC2 complex accelerated tumor progression suggesting that the polycomb repressor PRC2 has tumor-suppressive activity. We showed that the catalytic activity of EZH2 is required for acceleration of tumor progression and potential clinical vulnerability (Fig. 6) [14]. These results suggested that EZH2 might be an oncogene, whereas KDM6A/UTX might have tumor-suppressive activity. To address whether EZH2 might have oncogenic activity, we recently deleted EZH2 and SUZ12 in mouse and human G3 MBs by TALEN and CRISPR-Cas9 gene editing approaches [33]. Contrary to our expectation, loss of the PRC2 complex accelerated tumor progression suggesting that the polycomb repressor PRC2 has tumor-suppressive activity. We showed that the catalytic activity of EZH2 is required for acceleration of tumor progression and potential clinical vulnerability (Fig. 6) [14]. These results suggested that EZH2 might be an oncogene, whereas KDM6A/UTX might have tumor-suppressive activity. To address whether EZH2 might have oncogenic activity, we recently deleted EZH2 and SUZ12 in mouse and human G3 MBs by TALEN and CRISPR-Cas9 gene editing approaches [33]. Contrary to our expectation, loss of the PRC2 complex accelerated tumor progression suggesting that the polycomb repressor PRC2 has tumor-suppressive activity. We showed that the catalytic activity of EZH2 is required for acceleration of tumor progression and potential clinical vulnerability (Fig. 6) [14]. These results suggested that EZH2 might be an oncogene, whereas KDM6A/UTX might have tumor-suppressive activity. To address whether EZH2 might have oncogenic activity, we recently deleted EZH2 and SUZ12 in mouse and human G3 MBs by TALEN and CRISPR-Cas9 gene editing approaches [33]. Contrary to our expectation, loss of the PRC2 complex accelerated tumor progression suggesting that the polycomb repressor PRC2 has tumor-suppressive activity. We showed that the catalytic activity of EZH2 is required for acceleration of tumor progression and potential clinical vulnerability (Fig. 6) [14]. These results suggested that EZH2 might be an oncogene, whereas KDM6A/UTX might have tumor-suppressive activity. To address whether EZH2 might have oncogenic activity, we recently deleted EZH2 and SUZ12 in mouse and human G3 MBs by TALEN and CRISPR-Cas9 gene editing approaches [33].

Previous in vitro studies in MB cell lines using shRNA or the EZH2 inhibitor DZNEP suggested that EZH2 had oncogenic activity [35]. This apparent opposite function of EZH2 found in the two studies might be due to either the difference between the complete deletion of the protein rather than suppressing its expression or the use of cell lines passaged on plastic rather than primary tumors passaged only in mouse brain. Deletion of EZH2 in one patient-derived xenograft of
G3 MB, Icb1572, never passaged in vitro, accelerated tumor progression, consistent with data in mouse G3 MBs (Bao-Han Vo and Martine F. Roussel, unpublished results).

In accord with a context-dependent role of EZH2 as a tumor suppressor or an oncogene, targeted disruption of EZH2 by shRNA or EZH2 inhibitory drugs strongly suppressed the proliferation of other models of pediatric brain tumors. Several companies have now developed small molecules, targeting EZH2 and EED, some of which are currently in clinical trials [36]. Based on our studies using CRISPR-Cas 9 genome editing in mouse and human G3 MBs, a more thorough understanding of the consequences of tumor-specific epigenetic perturbation is warranted to avoid potentially detrimental therapeutic outcomes of EZH2 or EED inhibitory drugs in patients with medulloblastoma expressing high levels of EZH2.

**Chromatin-Remodeling Complexes and Enhancer Dynamics in Medulloblastoma**

ATP-dependent chromatin remodeling complexes represent another mechanism by which histone-DNA dynamics can be altered. This class of complexes promotes the accessibility of DNA and facilitates transcription factor migration and/or histone exchange [10]. Recurrent mutations in SWI/SNF family members including SMARCA4 are identified in medulloblastoma, typically restricted to WNT and G3 subgroups [9, 37]. SWI/SNF and PRC2 complexes exhibit epigenetic antagonism, a phenomenon that has inspired the evaluation of PRC2 inhibitors in SWI/SNF mutant pediatric cancers [38]. Inactivating mutations in ZMYM3, a histone binding protein that typically promotes DNA integrity and contributes to the regulation of gene transcription at the H3K4me3 mark, occur exclusively in G4 tumors [39]. ZMYM3 mutations are often found in conjunction with KDM6A/UTX mutations and submedian EZH2 expression, suggestive of a cooperative role and further supporting the importance of H3K27/H3K4 modulation in MB [9]. Mutations in DDX3X, a DEAD-box RNA helicase which plays a role in chromosomal segregation and cell cycle progression, are enriched in WNT subgroup MB and are thought to contribute directly to pathogenic β-CATENIN signaling [9].

Large-scale chromatin remodelers, including NuRD complexes, also play a role in enhancer dynamics, as contributing co-repressors or co-activators [40]. In addition to chromatin modifications in these non-coding elements driven by mutations in enhancer-associated H3K4 methyltransferases and H3K27 demethylases, MLL3/MLL4 (KMT2C/B) and KDM6A/UTX, respectively, structural rearrangements resulting in enhancer hijacking have also been described in G3 and G4 MB [34]. Changes in the enhancer landscape may contribute to inappropriate activation of oncogenes or inactivation of tumor suppressors. Recent work suggests that a putative target of enhancer hijacking, PRDM6, a presumed HMT, may serve as a prevalent driver in G4 MB [4]. Resulting “enhancer signatures” are now being investigated in MB, and other cancers, as an underlying disease mechanism and potential therapeutic vulnerability [40].
MicroRNAs and Long Non-Coding RNAs in Medulloblastoma

The miRNAs’ and LncRNAs’ landscape in medulloblastoma has been described in the last 10 years, and some have been validated in mouse models [41]. miRNAs are short (19–25) nucleotide sequences that bind to mRNAs of protein-coding genes usually in the 3’-untranslated region of the targeted mRNA leading to translational repression or its degradation. miRNAs are generated from long transcripts encoded by the genome that are initially processed in the nucleus by the RNase III Drosha as pre-miRNAs. Pre-miRNAs are then transported into the cytoplasm where they are cleaved by Dicer into mature miRNAs. In turn, miRNAs are incorporated into the RNA-induced silencing complex (RISC) to bind to their specific mRNAs [42]. The first miRNA reported in medulloblastoma was miR-124. Its expression is suppressed in MBs leading to overexpression of CDK6. CDK6, the catalytic partner of cyclin D2/CCND2 and cyclin D3/CCND3 that phosphorylates RB to drive cells through the G1 phase of the cell cycle, confers a poor prognosis in MB [43]. Another polycistronic miRNA miR-17–92 was found to be overexpressed and to have oncogenic activity in SHH medulloblastoma [19, 44]. miRNAs can be either upregulated (miR-17–92) or downregulated (miR-124) in medulloblastoma, as in other cancers, suggesting that they could be used therapeutically. Consistent with its oncogenic activity, suppression of the miRNA-17–92 cluster by anti-miRNAs inhibits SHH medulloblastoma development, whereas its enforced expression instead accelerates SHH tumor formation [45]. Interestingly, miRNA-17–92 is a target of MYCN, a direct target of SHH signaling that is overexpressed by amplification in SHH MBs [46]. Many other miRNAs have been identified in each MB subgroup although the targets that they regulate have not been identified and will need validation in mouse models and patient-derived xenografts of medulloblastoma.

LncRNAs are RNAs that are transcribed in an antisense manner from any given genomic loci. Their function has been attributed to regulate integrity of the nuclear structure, regulation of gene expression, and/or post-transcriptional processing [41]. Whereas LncRNAs are aberrantly expressed in the development of the nervous system, their role and number in medulloblastoma is relatively uncharted. A recent publication identified a LncRNA (Linc-NeD125) overexpressed in G4 MBs. This LncRNA sequesters the RISC complex containing three miRNAs, miR-19a, miR-19b, and miR-106a, encoded by the miR-17–92 cluster, leading to the de-repression of their targets, including CDK6, MYCN, KDM6A/UTX, and SNCAIP, all major drivers of G4 MB. Consistent with the role of the miR-17–92 as an oncogene, the ectopic expression of the Linc-NeD125 suppressed G3 MB proliferation, migration, and invasion [47]. Another LncRNA that is awaiting validation is PVT1 since it is amplified together with MYC in MBs [48]. Although few LncRNAs have been identified and validated in MBs, these recent studies suggest that they could be used therapeutically in the future. A better understanding of both microRNA and LncRNA function and dysregulation in MB may provide novel pharmacological targets.

Conclusion

With the ultimate goal of identifying therapeutic vulnerabilities, the validation of epigenetic regulators in mouse models and patient-derived xenografts of MB should contribute to both the basic and translational understanding of MBs.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Taylor MD, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123(4):465–72.
2. Roussel MF, Robinson GW. Role of MYC in medulloblastoma. Cold Spring Harb Perspect Med. 2013. https://doi.org/10.1101/cshperspect.a014308.
3. Schwabie EC, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma:a cohort study. Lancet Oncol. 2017;18(7):958–71.
4. Northcott PA, et al. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017;547(7663):311–7.
5. Cavalli FMG, et al. Inter-tumoral heterogeneity within medulloblastoma subgroups. Cancer Cell. 2017;31(6):737–54.
6. Packer RJ, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24(25):4202–8.
7. Needle MN, et al. Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood. Cancer. 1997;80(2):341–7.
8. Gajjar A, Finlay JL. The management of children and adolescents with medulloblastoma in low and middle income countries. Pediatr Blood Cancer. 2015;62(4):549–50.
9. Robinson G, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012;488(7409):43–8.
10. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27–36.
11. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148–59.
12. Pugh TJ, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012;488(7409):106–10.
13. Jones DT, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012;488(7409):100–5.
14. Dubuc AM, et al. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol. 2013;125(3):373–84.

15. Schwalbe EC, et al. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol. 2013;125(3):359–71.

16. Shahi MH, et al. Regulation of sonic hedgehog-GLI1 downstream target genes PTCH1, Cyclin D2, Plakoglobin, PAX6 and NKKX2.2 and their epigenetic status in medulloblastoma and astrocytoma. BMC Cancer. 2010;10:614.

17. Shahi MH, et al. Human hedgehog interacting protein expression and promoter methylation in medulloblastoma cell lines and primary tumor samples. J Neuro-Oncol. 2011;103(2):287–96.

18. Pfister S, et al. Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. Nucleic Acids Res. 2007;35(7):e51.

19. Northcott PA, et al. Multiple recurrent genetic events converge on medulloblastoma. Nat Genet. 2009;41(4):465–72.

20. Pfister S, et al. The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer. 2008;122(6):1207–13.

21. Milde T, et al. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res. 2010;16(12):3240–52.

22. Ma JX, et al. Expression patterns and potential roles of SIRT1 in human medulloblastoma cells in vivo and in vitro. Neuropathology. 2013;33(1):7–16.

23. Li XN, et al. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21/Cip1, CDK4, and CMYC. Mol Cancer Ther. 2005;4(12):1912–22.

24. Delmore JE, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904–17.

25. Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54(5):728–36.

26. Bandopadhayay P, et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014;20(4):912–25.

27. Henssen A, et al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget. 2013;4(11):2080–95.

28. Lee TI, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 2006;125(2):301–13.

29. Boyer LA, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006;441(7091):349–53.

30. Cao R, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298(5595):1039–43.

31. O’Carroll D, et al. The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol. 2001;21(13):4330–6.

32. Bachmann IM, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24(2):268–73.

33. Vo BT, et al. Inactivation of Ezh2 upregulates Gfi1 and drives aggressive Myc-driven group 3 medulloblastoma. Cell Rep. 2017;18(1):1–11.

34. Northcott PA, et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Cell Rep. 2017;20(2):360–9.

35. Alimova I, et al. Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer. 2012;131(8):1800–9.

36. Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22(2):128–34.

37. Parsons DW, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011;331(6016):435–9.

38. Wilson BG, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010;18(4):316–28.

39. Leung JW, et al. ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair. Genes Dev. 2017;31(3):260–74.

40. Herz HM. Enhancer deregulation in cancer and other diseases. BioEssays. 2016;38(10):1003–15.

41. Huarte M. The emerging role of IncRNAs in cancer. Nat Med. 2015;21(11):1253–61.

42. Maefarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics. 2010;11(7):537–61.

43. Pierson J, et al. Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neuro-Oncol. 2008;90(1):1–7.

44. Uziel T, et al. The miR-17–92 cluster collaborates with the sonic hedgehog pathway in medulloblastoma. Proc Natl Acad Sci U S A. 2009;106(8):3249–54.

45. Murphy BL, et al. Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. Cancer Res. 2013;73(23):7068–78.

46. Northcott PA, et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res. 2009;69(8):3249–55.

47. Laneve P, et al. The long noncoding RNA linc-NeD125 controls the expression of medulloblastoma driver genes by microRNA sponge activity. Oncotarget. 2017;8(19):31003–15.

48. Northcott PA, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012;488(7409):49–56.